Effect of RECK in Posterior Spinal Fusion

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new combination of pain relief medications called RECK, which stands for Ropivacaine, Epinephrine, Clonidine, and Ketorolac. The main goal of the study is to see if using RECK as a local injection during spinal fusion surgery can help reduce pain after surgery, lower the need for opioid painkillers, and shorten the time spent in the hospital. Participants will be monitored for how much pain they feel after the surgery and how much medication they need for pain control.

To be eligible for this trial, participants must be between 18 and 88 years old and scheduled to have spinal fusion surgery on one to three lumbar (lower back) levels. However, people who have had previous surgeries on their spine, have surgery for trauma, tumors, or infections, or have certain serious health conditions won’t be able to participate. This study is still in the planning phase and has not started recruiting participants yet. If you or a loved one are considering this surgery, this trial may offer an innovative approach to managing postoperative pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-88 years old
• • Undergoing spinal fusion at 1-3 lumbar levels via a posterior approach.
• Exclusion Criteria:
• • Revision surgeries
• • Surgeries indicated for trauma, tumor, or infection
• • Preoperative history of moderate to severe hepatic, renal, cardiac, or psychiatric illness
• • Known hypersensitivity to any of the RECK components